Post by Bristol Myers Squibb on X
Bristol Myers Squibb@bmsnews
X#MEDIA: Announcing @US_FDA has accepted the application for our dual #immunotherapy combination as a potential first-line treatment option for patients with unresectable or metastatic MSI-H or dMMR #colorectalcancer. t.co
24 likes1 repliesPosted Feb 24, 2025